Fat and Sugar

Boeva O.I.; Koretskaya N.E.; Rzhevskaya E.V.; Oleynikova V.D.

Ольга Игоревна Боева

ИКМ ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский Университет)

SPIN РИНЦ: 4110-8448
Scopus AuthorID: 57208068531
ORCID: 0000-0002-8699-1233

Наталья Евгеньевна Корецкая

ФГБУ «Поликлиника № 1» Управления делами Президента Российской Федерации

ORCID: 0009-0008-3217-3578

Елена Васильевна Ржевская

ФГБУ «Поликлиника № 1» Управления делами Президента Российской Федерации

SPIN РИНЦ: 8558-0306
Scopus AuthorID: 57224909367
ORCID: 0000-0001-7194-8219

Виктория Дмитриевна Олейникова

ИКМ ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский Университет)

ORCID: 0000-0002-1304-6046

Жир и сахар

Авторы:

Боева О.И., Корецкая Н.Е., Ржевская Е.В., Олейникова В.Д.

Подробнее об авторах

Журнал: Non nocere. Новый терапевтический журнал. 2025;(11): 44‑52

Прочитано: 143 раза

Связаться с автором

Оглавление

Как цитировать:

Боева О.И., Корецкая Н.Е., Ржевская Е.В., Олейникова В.Д. Жир и сахар. Non nocere. Новый терапевтический журнал. 2025;(11):44‑52.
Boeva OI, Koretskaya NE, Rzhevskaya EV, Oleynikova VD. Fat and Sugar. Non Nocere. New Therapeutic Journal. 2025;(11):44‑52. (In Russ.)

Использование инфографики авторами научных работ

Литература / References:

Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. https://doi.org/10.1016/j.jacc.2022.11.005
Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, Ramli AS, Lai NM. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open. 2021 Dec 3;11(12):e049662. https://doi.org/10.1136/bmjopen-2021-049662
Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):25-32. https://doi.org/10.1177/2047487319878371
Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020 Jul 15;370:m2297. https://doi.org/10.1136/bmj.m2297
Neves JS, Newman C, Bostrom JA, et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract. 2022 Aug;190:109980. https://doi.org/10.1016/j.diabres.2022.109980
Bordeianu G, Mitu I, Stanescu RS, et al. Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis-Literature Review. Diagnostics (Basel). 2022 Dec 13;12(12):3141. https://doi.org/10.3390/diagnostics12123141
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022 May;75(5):429. English, Spanish. https://doi.org/10.1016/j.rec.2022.04.003
Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 2019 Jun 7;18(1):134. https://doi.org/10.1186/s12944-019-1080-x
Doi T, Nordestgaard BG, Langsted A. Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):128-135. https://doi.org/10.1097/MED.0000000000000799
Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012 Dec;225(2):444-449. https://doi.org/10.1016/j.atherosclerosis.2012.08.039
Zhao M, Xiao M, Tan Q, Ji J, Lu F. Cumulative residual cholesterol predicts the risk of cardiovascular disease in the general population aged 45 years and older. Lipids Health Dis. 2024 Jan 19;23(1):19. https://doi.org/10.1186/s12944-023-02000-0
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140. https://doi.org/10.1093/eurheartj/ehad192
Wadström BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023 Apr 21;44(16):1432-1445. https://doi.org/10.1093/eurheartj/ehac822
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455
Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471
Georgoulis M, Chrysohoou C, Georgousopoulou E, et al. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012). Lipids Health Dis. 2022 Dec 19;21(1):141. https://doi.org/10.1186/s12944-022-01747-2
Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur J Clin Nutr. 2018 Jan;72(1):30-43. https://doi.org/10.1038/ejcn.2017.58
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1–S127. https://doi.org/10.1016/j.kint.2022.06.008
Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis. 2023 Jul–Aug;79:2-11. https://doi.org/10.1016/j.pcad.2023.03.001
Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022 Feb 22;43(8):830-833. https://doi.org/10.1093/eurheartj/ehab718
ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes – 2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S158–S190. https://doi.org/10.2337/dc23-S010
Gaita D, Gaita L, Mihaescu A. Non-HDL cholesterol series: PCSK9 inhibitor new season! Eur J Prev Cardiol. 2020 Oct;27(15):1661-1662. https://doi.org/10.1177/2047487320913375
Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. https://doi.org/10.1056/NEJMoa1912387
Правительство Российской Федерации. Распоряжение от 15 января 2025 года №10-р [Электронный ресурс]. Дата обращения: 20.08.2025. https://static.government.ru/media/files/QReCGT23cFXJslbQwJkh8koUBQa5lydA.pdf
Heo JH, Jo SH. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease. J Korean Med Sci. 2023 Sep 25;38(38):e295. https://doi.org/10.3346/jkms.2023.38.e295
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25): e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016 Jul–Aug;10(4):905-914. https://doi.org/10.1016/j.jacl.2016.03.008
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-1861. https://doi.org/10.1016/S0140-6736(05)67667-2
ACCORD Study Group; Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-1574. https://doi.org/10.1056/NEJMoa1001282
Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022 Nov 24;387(21):1923-1934. https://doi.org/10.1056/NEJMoa2210645
Kim NH, Kim SG. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes Metab J. 2020 Apr;44(2):213-221. https://doi.org/10.4093/dmj.2020.0001
Rudkowska I, Verreault M, Barbier O, Vohl MC. Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment. PPAR Res. 2009;2009:369602. https://doi.org/10.1155/2009/369602
Xu X, Guo H, Jing Z, et al. N-Oleoylethanolamine Reduces Inflammatory Cytokines and Adhesion Molecules in TNF-α-induced Human Umbilical Vein Endothelial Cells by Activating CB2 and PPAR-α. J Cardiovasc Pharmacol. 2016 Oct;68(4):280-291. https://doi.org/10.1097/FJC.0000000000000413
Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2017 Apr 1;2(4):370-380. https://doi.org/10.1001/jamacardio.2016.4828
Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022 Jul 13;43(4):611-653. https://doi.org/10.1210/endrev/bnab037
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. https://doi.org/10.1056/NEJMoa1707914
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. https://doi.org/10.1056/NEJMoa2021372
Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. https://doi.org/10.1056/NEJMoa1912388
Boltri JM, Tracer H, Strogatz D, et al. The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes. Diabetes Care. 2023 Feb 1;46(2):e39–e50. https://doi.org/10.2337/dc22-0620
Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138–e140. https://doi.org/10.1093/cvr/cvab231
Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023 Oct;82(4):279-285. https://doi.org/10.1016/j.jjcc.2023.05.006
Lucero D, Dikilitas O, Mendelson MM, et al. Transgelin: a new gene involved in LDL endocytosis identified by a genome-wide CRISPR-Cas9 screen. J Lipid Res. 2022 Jan;63(1):100160. https://doi.org/10.1016/j.jlr.2021.100160